Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCTBiotechnology
Healthcare
$8.04 +1.97%
+$0.15 today
- Market cap
- $231.73M
- Beta
- 2.35
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$2.77
52W Low $5.85High $24.17
Volume 0.64M
Average 0.43M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$74.27M
FY 2025 · Annual
Investing Cash Flow
-$230,000.00
FY 2025 · Annual
Financing Cash Flow
$13.38M
FY 2025 · Annual
+147.0% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (203.67M) | 9.35M | (29.73M) | (80.94M) | (65.78M) |
| Depreciation & Amortization | 1.19M | 1.53M | 2.96M | 3.54M | 3.03M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 28.92M | 30.61M | 34.65M | 37.99M | 25.41M |
| Change in Working Capital | 32.63M | (12.56M) | 7.38M | (20.81M) | (39.2M) |
| Accounts Receivables | (1.24M) | 603K | (29.3M) | 28.09M | (1.59M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (769K) | (3.11M) | (2.24M) | 1.92M | (2.96M) |
| Other Working Capital | 34.64M | (10.05M) | 38.92M | (50.81M) | (34.65M) |
| Other Non-Cash Items | 5.9M | 3.06M | (33.36M) | 471K | 2.28M |
| Operating Cash Flow | (135.04M) | 31.99M | (18.1M) | (59.75M) | (74.27M) |
| Capital Expenditures | (3.41M) | (7.73M) | (2.9M) | (648K) | (230K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (3.41M) | (7.73M) | (2.9M) | (648K) | (230K) |
| Debt Repayment | 46.6M | (5M) | (27.36M) | 0 | 0 |
| Common Stock Issued | 515K | 411K | 609K | 682K | 13.38M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 902K | 1.73M | 2.67M | 4.74M | 0 |
| Financing Cash Flow | 48.02M | (2.86M) | (24.09M) | 5.42M | 13.38M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (90.43M) | 21.41M | (45.09M) | (54.98M) | (61.12M) |
| Free Cash Flow | (138.45M) | 24.27M | (21M) | (60.4M) | (74.27M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$65.8M
+ D&A$3.0M
+ Stock-Based Comp$25.4M
+ Deferred Tax$0
- Working Capital-$39.2M
+ Other Non-Cash$2.3M
= Operating Cash Flow-$74.3M
- Capex-$230.0K
= Free Cash Flow-$74.3M
Analysis
FY2025 free cash flow is -$74.3M. FCF conversion is 112.9% of net income. Operating cash flow was -$74.3M, with capex of -$230.0K. The largest bridge item is Working Capital at -$39.2M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 29, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 7, 2026 |
Does ARCT generate free cash flow?
Arcturus Therapeutics Holdings Inc. (ARCT) generated -$74.27M of free cash flow in fiscal 2025.
How much operating cash flow does ARCT produce?
Operating cash flow was -$74.27M, before capital expenditures of $230,000.00.
Continue the stock analysis
Jump to another research area for this company.